Call for proposals
Most of the research that the MRC funds is in response to proposals by scientists, however from time to time we stimulate research in priority areas by publishing call for proposals. The list below displays all current calls. An archive of closed calls
is available for reference purposes.
UK-China Stem cell partnership development initiative
The MRC and the National Natural Science Foundation of China invites proposals to the UK-China Stem Cell partnership development initiative from high quality research teams based in the UK and China
Open
MRC/AstraZeneca: Mechanisms of Disease call for proposals
The MRC and AstraZeneca have worked together to provide access for UK academic researchers to a high-quality collection of AstraZeneca compounds.
Open
Stratified Medicine - Call for proposals for disease-focused partnerships to stratify disease for patient benefit
Researchers are now invited to submit outline proposals for funding for the development of disease-focussed consortia to stratify disease.
Open
Working with industry – developing a consortium to stratify diabetes
While the MRC has significant research investments in obesity and metabolic disease, there are opportunities for further collaboration between industry. Investigators are now invited to take part in developing a consortium to stratify diabetes.
Open
Joint Synthetic Biology Initiative
Researchers are invited to apply for funding from a new Joint Synthetic Biology Initiative, which has made up to £2.4 million available from the MRC, BBSRC, Dstl, and EPSRC.
Open
E-Health Informatics Research Centres (E-HIRCs) Call
The MRC and partners invite proposals for Centres of Excellence in research linking electronic health data.
Open
Opportunities to work in the new Research Complex at Harwell
Applications for the opportunity of being one of the initial occupants of the Research Complex are invited to the 2011 deadlines of current MRC funding schemes.
Open
European and developing countries clinical trials partnership
EDCTP. To accelerate development of new or improved drugs and vaccines, with a focus on phase II and III clinical trials and on Sub-Saharan Africa.
Open
